The Food and Drug Administration has approved Teva's Prolia biosimilar, and the agency is reviewing Teva's Xolair biosimilar application. “The FDA approval of Ponlimsi is a significant milestone that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results